Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib.

ABSTRACT:

Background

Serial analysis of biomarkers in the circulation of patients undergoing treatment ("liquid biopsies") can provide new insights into drug effects. In particular the analysis of cell-free, circulating nucleic acids such as microRNAs (miRs) can reveal altered expression patterns indicative of mechanism of drug action, cancer growth, and tumor-stroma interactions.

Results

Here we analyzed plasma miRs in patients with hormone receptor positive, metastatic breast cancer with prior disease progression during aromatase inhibitor therapy (n = 8) in a phase I/II trial with the multiple tyrosine kinase inhibitor dovitinib (TKI258). Plasma miR levels were measured by quantitative RT-qPCR before and after treatment with dovitinib. A candidate miR signature of drug response was

SUBMITTER: Shivapurkar N 

PROVIDER: S-EPMC5628092 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature